Ivabradine Generics [uk]

Ivabradine, the active ingredient in Ivabradine Generics, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used in chronic stable angina and heart failure with reduced ejection fraction in adults.

GNH USA supplies Ivabradine Generics as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to lower heart rate in specific cardiovascular conditions.

- Chronic stable angina: improves exercise tolerance by reducing heart rate. - Heart failure with reduced ejection fraction: decreases hospitalization risk through heart‑rate reduction. - Angina pectoris: alleviates chest pain by limiting myocardial oxygen demand.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Bradycardia: heart rate falls below expected levels. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness or light‑headedness.

Serious or Rare Side Effects: - Severe bradycardia requiring medical attention. - Atrial fibrillation or other arrhythmias. - Symptomatic hypotension or heart block.

Use ivabradine with careful clinical monitoring.

- Heart‑rate monitoring: check resting rate before and during therapy. - Hepatic impairment: avoid or adjust dose in severe liver disease. - Concomitant bradycardic agents: use caution with beta‑blockers or calcium‑channel blockers. - Sick sinus syndrome: contraindicated. - Discontinue if resting heart rate falls below 50 bpm. - Store at room temperature: keep in the original pack, protect from moisture.

Ivabradine may interact with several medicines.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase ivabradine exposure. - Concomitant beta‑blockers or other heart‑rate‑lowering drugs: risk of excessive bradycardia. - Diltiazem or verapamil: potentiate ivabradine effects via CYP3A4.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): may raise plasma levels. - Digoxin: combined use may enhance bradycardic risk.